Successful treatment with oseltamivir phosphate in children with ITP who failed first-line therapy: a case series...

Area of Science:

• Hematology
• Pediatrics
• Pharmacology

Background:

• Immune thrombocytopenia (ITP) is a prevalent pediatric bleeding disorder.
• Standard first-line treatments like glucocorticoids and immunoglobulin are ineffective for some children, leading to poor outcomes.
• Refractory ITP poses significant clinical challenges and necessitates alternative therapeutic strategies.

Purpose of the Study:

• To report the successful use of oseltamivir phosphate in children with ITP who did not respond to first-line treatments.
• To elucidate the mechanism by which oseltamivir phosphate increases platelet counts in ITP.

Main Methods:

• Case series reporting on three pediatric patients with ITP.
• Oral administration of oseltamivir phosphate granules as a therapeutic intervention.
• Investigation into the sialylation inhibition mechanism of oseltamivir phosphate on platelets.

Main Results:

• All three pediatric patients with refractory ITP achieved complete remission after treatment with oseltamivir phosphate.
• Oseltamivir phosphate demonstrated efficacy in increasing platelet counts.
• The mechanism involves inhibition of platelet sialylation, reducing platelet destruction by liver macrophages.

Conclusions:

• Oseltamivir phosphate is a viable and effective treatment option for pediatric immune thrombocytopenia refractory to standard therapies.
• The drug's mechanism of action, inhibiting platelet sialylation, provides a novel approach to managing ITP.
• These findings suggest a potential new therapeutic avenue for children with difficult-to-treat ITP.